Design, Spectroscopic, DFT,Pharmacological and Molecular DockingofRuthenium(III)-Schiff Base Complex; An Inhibitor of Progression in HepG2 Cells

Safa W. Aziz [1,2], Amani F.H. Noureldeen[1,]*, Samia A. Shouman[3], Magdy M. Mohamed [1], Yasmin M. Attia [3], Ramadan M. Ramadan [4],* and Mostafa M. Elhady[1]

[1] *Biochemistry Department, Faculty of Science, Ain Shams University, Cairo, Egypt.*
[2] *Department of Laboratory and Clinical Sciences, College of Pharmacy, University of Babylon,Iraq.*
[3] *Cancer Biology Department, National Cancer Institute, Cairo University.*
[4] *Chemistry Department, Faculty of Science, Ain Shams University, Cairo, Egypt.*

Abstract
A novel ruthenium(III)-pyrimidine Schiff base was synthesized and characterized using different analytical and spectroscopictechniques.Molecular geometries of the ligand and rutheniumcomplex were investigated using the DFT-B3LYPlevel of theory. The quantum global reactivity descriptorswere also calculated.Various biological and molecular docking studies of the complex are reported to explore its potential application as therapeutic drug.Cytotoxicity of the complex was screened against cancer colorectal (HCT116), breast (MCF-7 and T47D), hepatocellular (HepG2) cell lines as well as human normal cell line (HSF).The complex effectively inhibited the tested cancer cells with variable degree with higher activity towards HepG2.The complexinduced apoptosis and cell cycle arrest in the S phase of HepG2 cells.The complex significantly induced the expression of H2AX, and caspase 3 and caspase 7 gene and protein level of caspase 3 as well as inhibited VEGF-A, and mTOR /AKT, SND1, NFkB gene expression.The molecular docking studiessupported the increased the total apoptosis of treated HepG2 cells due to strong interaction of the complex with DNA. Also, the possible binding interaction of the complex with caspase 3 could be responsible for the elevated activity of caspase 3treated cells.
Keywords:*ruthenium Schiff base complex; DFT studies, antitumor activity, DNA damage, cell cycle arrest, apoptosis, molecular docking.*

I. Introduction

Globally Hepatocellular carcinoma (HCC) is one of the leading lethal tumors worldwide; it is the third cause of cancer-related death.[1] Its incidence, morbidity, and mortality are high, especially in Asia and Africa.[2]HCC is multifactorial in etiology, where contamination of foodstuffs to hepatic carcinogens such as aflatoxin. In addition, the endemic high prevalence of hepatitis B and hepatitis C strongly predisposes to the development of chronic liver disease and subsequent development of HCC.[3] Surgery and chemotherapy are the current standard curative methods for patients with HCC at an early stage, but the prognosis is still flawed. Therefore, other effective therapeutic strategies with lower costs and fewer side effects are urgently required for the treatment of HCC.

Platinum-based drugs such as cisplatin, oxaliplatin and carboplatin are widely used in chemotherapy treatments. They play important role in fighting many types of cancer like testicular, ovarian, bladder, cervical, hepatic and lung cancers. They obstruct the DNA from replicating and from acting as a rout for proteins making. However, these platinum-based drugs cause terrible side effects including severe nausea, vomiting, critical anemia, hair loss, susceptible to infections as well as they destroy the patients' kidneys and livers. Thus, the problems of such severe symptoms encouraged the developing of novel metal-complexes able to interact with DNA and have potential anticancer activity along with light side effects. Therefore, researchers seek out for other metal-based drugs gold(III), gold(I), ruthenium(II) and ruthenium(III) complexes.In particular, ruthenium complexes have received a lot of attention as an alternative to platinum-baseddrugs due to their good biodistribution and multimodal actions.[4-6]Numerous ruthenium complexes exhibited remarkable antitumor activity and some of them have various advantages over platinum drugs such as potent efficacy, less drug resistance, and low toxicity.[7-9]Ruthenium complexes proved to be successfully able to penetrate the tumor cells and to bind effectively to the nucleic acids. Thus, ruthenium complexes presented great research subjects

and they are tested for their effects versus the different cell lines of cancer. These complexes are noted to be promising substitute selects instead of cisplatin and its derivativesand they are expected to become a new generation of clinical metal antitumor drugs. Ruthenium derivatives are generally least toxic than other platinum drugs and they are most efficient against drug resistance induced by other drugs.Particularly,ruthenium complexes of Schiff base ligands succeeded to show good achievement for biological applications as antioxidant reagents, and antimicrobial and anticancer potential medications. This is probably because of the octahedral coordination preference of both ruthenium(II) and ruthenium(III) complexes. Such three-dimensional geometrical frameworks may provide potential elevation of site selectivity for better binding to the biologically active macromolecular receptors. These molecular structure arrangements may also cause deactivation of tumor suppressor gene (p53) in the cells of cancer. Furthermore, they can overcome the bad chemotherapeutic results and the clinical drugs resistance.[10-12]

The development of new antitumor drugs requires understanding the mechanisms of action of new pharmacological candidates, which highlights the importance of elucidating the molecular and biochemical mechanisms involved. For example, some ruthenium complexes target the genomic DNA and may cause cell cycle arrest, ROS-mediated mitochondrial alterations, and cell death by apoptosis.[13]It is worth to mention that there are already some ruthenium complexes haveenteredthe clinical trials. The first candidate was an imidazolium complex, [RuCl$_4$(imidazole)(DMSO)](DMSO = dimethyl sulfoxide), that reaches the phase II stage study on human beings.[14]Another promising Ru(III) complex that have entered clinical trials is an indazole complex, [trans-RuCl$_4$(indazole)$_2$].[15,16]

Our interest in synthesizing and investigatingthe biological and medicinal activity of the Ru(II) and Ru(III) Schiff base complexes as potential anticancer agents[6,11,17,18]has prompted us to design more novel Schiff base-ruthenium complexes. Here, we report the synthesis, spectroscopic, DFT, pharmacological and molecular docking studies of aruthenium(III)-pyrimidine Schiff base complex(**RuL**, **Ru** = RuCl$_3$(H$_2$O); **L** = Schiff base ligand, **Figure 1**) as it was found to bean inhibitor for progression in HepG2 cells.

II.   Experimental

2.1. Materials and Instruments
Ruthenium(III) chloride, 2-amino-4,6-dimethylpyrimidine and 2-chloro-5-nitrobenzaldehyde were purchased from Aldrich. All the solvents were of analytical reagent grades.IR measurements (KBr pellets) were carried out on a Unicam-Mattson 1000 FT-IR spectrometer. NMR measurements were performed on a Spectrospin-Bruker 300 MHz spectrometer. Samples were dissolved in (CD$_3$)$_2$SO with the use of TMS as an internal reference. Elemental analyses were performed on a Perkin–Elmer 2400 CHN elemental analyzer. Mass spectrometry measurements of the solid compounds (70 eV, EI) were carried out on a Finnigan MAT SSQ 7000 spectrometer.

2.2. Synthesis of 2-chloro-5-nitrophenyl-(4,6-dimethylpyrimidinyl)methanimine Schiff base; L
A mixture of ethanolic solution (30 mL) of 2-amino-4,6-dimethylpyrimidine (1.23 g, 10 mmol) and 2-chloro-5-nitrobenzaldehyde (1.85 g, 10 mmol) was refluxed for 3 h. The resulting pale-yellow solution was left to stand overnight at room temperature. The isolated yellowish-white solid product was filtered off and washed several times with ethanol. The residue was then recrystallized from hot ethanol to give fine crystals of the compound (yield 92 %).
C$_{13}$H$_{11}$N$_4$O$_2$Cl. Elemental analysis, found (Calc.): % C, 53.63(53.71); % H, 3.85(3.81); % N, 19.14(19.27). Mass spectrometry: M.M = 290.71; m/z = 291, 292. IR data, cm^{-1}: νC=N, 1596(s),1577(s); ν_{as}NO$_2$, 1523(s,b); ν_sNO$_2$, 1346(s). NMR data, ppm: 10.32s (1H, CH=N), 8.53-6.31m (4H, -Ph), 2.23s (3H, -CH$_3$), 2.16d (3H, -CH$_3$).

2.3. Synthesis of the(trichloro)(monoaquo)(2-chloro-5-nitrophenyl-(4,6-dimethylpyrimidinyl)-methanimine)ruthenium(III)complex; RuL
1 mmol solution of metal salt (RuCl$_3$.3H$_2$O, 0.26 g) in 20 ml EtOH was added to 1mmol solution of the Schiff base (0.29 g) dropwise, and then refluxed with stirring for 5 h at 80 °C. The obtained precipitate was filtered off, washed with ethanol. The crude was recrystallized from hot ethanol, and fine brown crystals were obtained. The crystals were left to dry in air for few hours (yield 78 %).
C$_{13}$H$_{13}$N$_4$O$_3$Cl$_4$Ru. Elemental analysis,found (Calc.): % C, 30.35(30.25); % H, 2.66(2.54); % N, 10.65(10.86). Mass spectrometry: M.M = 516.14; m/z = 516, 517, 518, 519, 520. IR data, cm^{-1}: νOH, 3417(s,b); νC=N, 1719(s), 1639(s), 1602(s); ν_{as}NO$_2$, 1523(m); ν_sNO$_2$, 1346(m); νRu-N, 574(w), 519(w).

2.4. Computational details
All calculations were performed using the hybrid density functional theory (DFT/ B3LYP) method as implemented in the Gaussian09 software package.[19]The geometry of the ligand atoms were optimized using the standard double zeta plus polarization basis set 6-31G (d,p), while the effective core potential basis set LANL2DZ was used for ruthenium complex. The purpose of the quantum mechanics calculations validates the proposed 3D structure of the ligand and Ru complex as well as to find key factors for their activities.

2.5. In vitro studies

2.5.1 Cancer cell lines

To test the anticancer activity of the reported ruthenium complex (**RuL**), four human cancer cell lines (breast, MCF-7 and T47D, colorectal, HCT116, and hepatocellular, HepG2, along with normal Human Splenic Fibroblasts, HSF, were screened. They were originally obtained from the American Type Culture Collection (ATCC; Washington, DC, USA), and then were maintained by serial sub-culturing at the National Cancer Institute (NCI, Cairo, Egypt).

2.5.2. Cytotoxicity assay

Cytotoxicity of the reported **RuL** was examined using cancer MCF-7, T47D, HCT116, and HepG2 cells lines as well as normal cell HS. The cancer cell lines were maintained in RPMI-1640 supplemented with 10% fetal bovine serum and 2 mM L-glutamine, 100 µg/ml streptomycin and 100 U/ml penicillin and incubated in a humidified 5% CO_2 atmosphere. Cells viability was assayed using sulphorhodamine B (Sigma-Aldrich, St. Louis, MO, USA) method as previously described.[20] In brief, 1.5×10^3 cells/well were seeded in 96-well plates; after 24 h later cells were exposed to different concentrations (10-100 µM) of the compound for 48 h. Absorbance at 540 nm was measured with an ELISA reader (Tecan Sunrise, Männedorf, Switzerland). Each concentration was repeated in triplicates and the experiment was repeated three times. Cell viability was expressed as the percentage of absorbance of the compound-treated cells relative to that of the vehicle-treated cells. The IC_{50} and 95% CL were evaluated. According to the results, the **RuL** showed the largest cytotoxcicity effect against HepG2 cells.

2.5.3. Annexin V / propidium iodide staining for apoptosis assessment

The following tests were carried out using HepG2 cells and the **RuL** complex. An Annexin-V-Fluos staining kit (Fisher Scientific, Hampton, NH, USA) was used according to the manufacturer's instruction to test the effect of the complex on apoptosis. The kit has double stains where, apoptotic cells and necrotic cells were stained with Annexin V (green fluorescence) and propidium iodide (PI, red fluorescence), respectively. HepG2 cells were grown to ~70% confluence and treated with 29 µM of the **RuL**(equivalent to IC_{50} value of the complex) for 48 h. After incubation, the floating and adherent cells were collected, washed three times with cold phosphate-buffered saline (PBS), followed by addition of 5 µL of annexin V and PI. The cells were incubated for 20 minutes and then analyzed by FACScan, Beckman Coulter Epics XL Flow Cytometer (USA).

2.5.4. Cell cycle analysis

HepG2 cells were seeded for 24 h at 70% confluence at 37 °C and 5% CO_2. Cells were treated for 48 hours with the concentration of IC_{50} of the **RuL** complex (29 µM). After the treatment incubation, the floating cells were aspirated and discarded. The cells were detached using trypsin then washed two times with cold PBS, followed by centrifugation. The pellet was resuspended with propidium iodide for 20 minutes for flow cytometry analysis. Flow cytometry was performed with a FACScan flow cytometer (Beckman Coulter Epics XL Flow Cytometer). A minimum of 10 000 cells/sample were collected, and cell cycle analysis was conducted.

2.5.5. Expression levels of caspase 3, VEGF-A, mTOR, NFkB, and SND1 by RT-PCR

HepG2 cells were seeded in 6-well plates, after 24 hours cells were treated with IC_{50} concentration of **RuL** for 48 hours. After the incubation time, cells were trypsinized and collected in tubes and then centrifuged for 5 min at 1200 rpm. The cellular total RNA was isolated from cells with Trizol reagent (Invitrogen, Carlsbad, CA, USA), and cDNA was obtained from 1 µg of total RNA using a SuperScript II reverse transcription kit according to the manufacturer's instructions (Invitrogen, Carlsbad, CA, USA). The cDNA was then amplified by PCR on a CFX384 Touch Real-Time PCR Detection System (Bio-Rad Laboratories, Hercules, CA, USA) using SYBR Green PCR Master Mix (Promega, Wisconsin, USA) according to the manufacturer's protocol. Fast amplification parameters were as follows: one cycle of 95°C for 10 minutes, followed by 40 cycles of 95°C for 15 seconds and 60°C for 1 minute. The primer sequences are shown in **Table 1S**. Quantitative analysis of data was performed as described previously). Values were normalized to GAPDH and are shown as relative expression levels.

2.5.6. Assay of protein levels of caspase 3, VEGF-A, mTOR, NFkB, and SND1.

The protein levels of caspase-3, VEGF-A, mTOR, NFkB, and SND1 were assessed spectrophotometrically at 450 nm in cell lysate using ELISA kit (Invitrogen, Carlsbad, CA, USA) following the manufacturer's instructions. Cells were cultured in 75 cm3 flasks, left till 70–80 % confluent; cells were treated with **RuL** complex for 48 hours. Then, the treated and control cells were lysed in a RIPA lysis buffer containing protease inhibitors. Each concentration was repeated two times and the experiment was carried out three independent times. The activity was calculated relative to the corresponding protein content.

2.6. Molecular docking studies

Molecular docking studies were carried out using Molecular Operating Environment (MOE) software package version 2014.09. The macromolecule targets B-DNA (PDB ID: 1BNA) and caspase 3 (PDB ID: 3KJF)were used for docking the ruthenium complex. 1BNA is an X-ray crystal structure of a B-DNA (dodecamer d (CGCGAATTCGCG)$_2$ running 3'-5' direction.[21]3KJF is a caspase-3 protein, which has a central role in programmed cell death.[22] Structures of the targets were energetically optimized after inserting hydrogen atoms. The resulting model afforded to systematic conformational research with RMS gradient of 0.01 kcal/mol.

2.7. Statistical analysis

All data are expressed as mean ± SD unless otherwise specified. Differences between treated samples and untreated controls were analyzed by *T*-test. Statistical analyses were performed using GraphPad Stat, version 7.03 (GraphPad, San Diego, CA, USA). Statistical significance was set at *P*< 0.05.

III. Result and Discussion

The reported Schiff base ligand and its ruthenium complex were synthesized and characterized using different spectroscopic techniques (IR, ^{1}H NMR, mass) as well as elemental analyses. The mass spectra of the two compounds showed theparent molecular peaks signals with the expected pattern. The obtained elemental analyses and spectroscopic data (**Materials and Methods section**) of the two compounds were in accordance with the proposed molecular formulas.

3.1. Spectroscopic studies

The IR spectra (KBr pellets) of the reported compounds were recorded in the region 4000-400 cm^{-1} (**Figure 1S**). The most prominent IR bands of the important functional groups, such as νOH, νC=N, ν_{as}NO$_2$ and ν_{as}NO$_2$,are given in the**Materials and Methods section**. The IR spectrum of the ligand displayed bands at 1596 and 1577 cm^{-1} due to stretching frequencies of two distinct C=N bonds, **Figure 1**. Interestingly, the IR spectrum of the Ru complex exhibited three bands due to three different C=N bonds (**Figure1**); these bands were shifted to higher wavenumbers as expected. In addition, the IR spectrum of the complex displayed non-ligand bands corresponding to Ru-N bonds.[23]The ^{1}H NMR spectrum of the ligand (**Figure 2S**) displayed a sharp singlet at 10.32 ppm due to the proton of the azomethine moiety.[24]In addition, the spectrum exhibited multiplets due to the phenyl protons as well as signals due to the methyl groups.

3.2. Stereochemistry and chemical reactivity prediction

The optimized structural, geometrical parameters and energetics of the ground state for the Schiff base ligand and its ruthenium complex were calculated using density functional theory (DFT). The structure of the ligand was optimized using the B3LYP/6-311G (double zeta) level of theory, while the effective core potential basis set LANL2DZ was used for optimization of ruthenium complex. In order to investigate the stereochemistry of the most stable structures, It was focused first on the structure of the Schiff base molecule; more specifically on the orientation of its functional groups with respect to each other and with respect to the central azomethine (HC=N) moiety. **Table 1** gives the important bond lengths and bond angles for both ligand and ruthenium complex. All the calculated bond lengths and bond angleswere in the normal range observed before.[25-27]The energetically stable model for the ligand with a minimization energy of 23.96 kcal/mol showed specific features, where the molecule is non-planer. The dihedral angles N(13)-C(12)-N(15)-C(8), C(4)-C(5)-C(8)-N(15) and C(5)-C(8)-N(15)-C(12) were 73.1^o, 137.9^o and176.1^o, respectively (**Figure2A**). The two bond distances involved in the azomethine group, C(12)-N(15) and C(8)-N(15), were 1.40 Å and 1.28 Å, respectively. Obviously, the latter bond is shorter due to the double bond characteristic. The bond angle of the azomethine part, C(5)-C(8)-N(15), N(11)-C(12)-N(15) and C(8)-N(15)-C(12) were 127.6^o, 123.2^{o}and 131.0^o, respectively. The orientation of the functional groups of the ligand suggested that it may only coordinate to the ruthenium ion through the nitrogen of the azomethine and one of the nitrogen atoms of the pyrimidine moiety, i.e., it can act as a bidentate ligand with the coordination of NN set of donors. **Figure2A** shows the charge distribution on the different atoms of ligand. The charge distribution showed that the two nitrogen atoms, N(15) and N(11), have the highly negative charge density relative to other atoms in the molecule (-0.32 and -0.40, respectively). Note that the oxygen atoms of the nitro group are not considered for coordination.

The optimized geometry (minimization energy 127.91 kcal/mol) and numbering of atoms of the ruthenium complex is presented in**Figure 2B**. The ruthenium coordinated to the ligand from two nitrogen atom donors (azomethine nitrogen and one of the nitrogen atoms of pyrimidine ring) to form a four membered chelate. In addition, the Ru completed its six-coordination environment by three chloro and a water molecule to adopt a distorted octahedral structure. The bond length of C(15)-N(11), which involved in the coordination was increased relative to that of ligand itself due to complex formation. Also, the bond angle N(11)-C(15)-N(20), which is participated in the chelate was significantly decreased from 123.2^o in the free ligand to 103.5^o due to complex formation. Notably, the water molecule coordinated trans to one of the chloro ligands with an angle

close to linearity (171.6°). Furthermore, the three chloro ligands coordinated cis to each and their angles deviated from ninety degree (around 100°) due to their electron pairs repulsion. On the other hand, the bond angle N(11)-Ru(30)-N(20) in the chelate was found to be 64.2°. Although the four membered chelate is unfavorable coordination due to the angles strain, the larger size of ruthenium helped in compensated such strain.

The global chemical reactivity parameters namely HOMO, LUMO, energy gap (*ΔE*), electronegativity (*X*), chemical potential (*V*), electron affinity (*A*), ionization potential (*I*), chemical hardness (*η*), chemical softness (*S*) and electrophilicity (*ω*) of the reported compounds are given in **Table 2**.[28]The frontier molecular orbital (HOMO and LUMO) energies were estimated using DFT method, **Figure3**. The HOMO orbital energy represents the electron donating ability, while the LUMO orbital energy characterizes the electron withdrawing ability. The energy gap between HOMO and LUMO shows the molecular chemical stability (reactivity); it is a critical parameter for determining molecular electrical transport properties. Smaller energy gap reflects the easiness of the charge transfer (CT), and the polarization, which occurs within the molecule.[29] Accordingly, the complex is more reactive than the ligand as it has the smaller energy gap. Furthermore, the electronegativity parameter is a reflection for the electrostatic potential, where the electron partially transferred from one of lower electronegativityto another of higher electronegativity. The results showed that ligand has lower *X* than the complex. The chemical potential of a species is the energy that can be absorbed or released due to a change of the particle number of the given species. Its value is arbitrary equal to the negative value of electronegativity. On the other hand, the results of small chemical hardness values for the two derivatives reflect the ability of charge transfer within the molecule. The order of increasing the charge transfer within the molecule is: **RuL**<**L**. Ionization potential is the minimum energy required to remove the most loosely bound electron from a neutral atom or molecule, while electron affinity is the amount of energy released when an electron is attached to a neutral atom or molecule to form a negative ion. From the HOMO and LUMO energies, ionization potential and electron affinity are expressed as I ~ $-E_{HOMO}$ and A ~ $-E_{LUMO}$. Electrophilicity index is a measure of the electrophilic power of a molecule. From **Table 2**, ligand has lower electrophilicity power relative to the complex.

3.3. In vitro studies
3.3.1. Cytotoxicity screening on thetested human cancer cell lines

The cytotoxic effect of **RuL**complex was screened on four different human cancer cell lines (breast, MCF-7 and T47D, colorectal, HCT116, and liver HepG2) using the Sulforhodamine B colorimetric (SRB) assay. The complex manifested antitumor activity on the tested cancer cell lines as shown in **Figure 4A**.For comparison, the effect of cisplatin toward the proliferation of HepG2 is also shown in **Figure 4B**. The results revealed that the **RuL**complex has a broad-spectrum antitumor activity.It could effectively inhibit all the tested human cancer cell lines as well as inhibits the growth with high anticancer activity.The obtained IC_{50} valueswrer 29 ± 3 μMfor HepG2, 38.5 ± 2 μMfor T47D, 39.7 ± 5.6 μMforHCT and 46.7 ± 7 μMforMCF-7cells.Thus, the**RuL** complex exhibited promising activity on the tested cell lines especially for HepG2 cell line; as it has smaller IC_{50}, which is comparable to that of cisplatin (29μM for **RuL** versus 22μMfor cisplatin). Notably, the cytotoxic effect of **RuL**complex on thenormal human splenic fibroblasts (HSF) was low as it has an IC_{50}higher than 100μM(**Figure4A**).Furthermore, for theHepG2 cancer cell line, **RuL** exhibited a selectivity index equal to 3.45, which islike that found for the positive control cisplatin. (The selectivity index, SI, iscalculatedfromthe formula:SI = $IC_{50}$of normal cells/$IC_{50}$of cancer cells). Based on the SI value, the **RuL** complex showed low toxicity towards the HSF human normal cells and indicates a high selectivity between cancer and normal cells.

3.3.2. Annexin V / propidium iodide staining for apoptosis assessment

Cell cycle and apoptosis are regulatory mechanisms of cell growth, differentiation, and development.[30]Mounting evidence shows that cell cycle arrest and apoptosis can reduce cancer cells viability and sensitize cancer cells to chemotherapy or radiotherapy.[31,32]The possible arrest of the cell cycle after exposure of HepG2 cells to IC_{50} dose of the**RuL** complex was analyzed using flow cytometry. As shown in **Figure5**, the ruthenium complex caused a reduction in the G0/G1 (98% vs 88%) phase accompanied by a corresponding increase in the percentage of cells in the S phase (0.85% vs 12%). These data suggested that the anti-proliferative mechanism forthe complex is based on S-phase arrest. Similar results were obtained previously by other ruthenium complexes.[33]One key strategy for the therapy of cancer is to induce cancer cell death through the development of drugs that induce apoptosis.[34]Moreover, the apoptotic effect of **RuL**on HepG2 cells was measured by Annexin V-FITC/PI using flow cytometry. Apoptosis and necrosis are two major types of cell death, and their deregulations can result in several diseases including cancer. The total apoptosis was defined as the sum of early and late apoptosis percentages. Flow cytometry results revealed that the total apoptosis of HepG2 cells treated with the complex was 5.8% versus 0.18 % in untreated control HepG2. The

percentage of necrotic cells after treatment with **RuL** was 48% versus 3.3% in the untreated control HepG2,**Figure6**.

3.3.3. Expression levels of caspase 3 and 7

It is well known that the Caspases family proteins function as important regulators in the induction of apoptosis.Caspase3and caspase7 are the key executioner enzymes that are necessary for apoptosis and for normalmammalian life. Caspase 3 is a relatively small protein that consists of 2 subunits,which contains 3 and 5 thiol function groups, respectively.[35]Activation of caspase 3 is dependent on its dimerization to a heterotetramer, where the histidine-activated Cys-285 in the active site of the p17 subunit is conserved in the caspase superfamily and is required for enzymatic activity. Caspase-3 is also activated by interaction with metal complexes.[33,36,37]Based on the obtained data of flow cytometry, the expression of apoptosis-related proteins displayed significantly increased expression levels of caspases 3 and 7 after treatment with the**RuL**complex (**Figure 7**). Furthermore, the protein level of caspase 3 was significantly increased after treatment compared with untreated cells.The findings indicated that the ruthenium complexinduced HCC cell apoptosis primarily through the activation of caspase-mediated apoptosis due to the proteolysis of the important cellular proteins.These results are consistent with previous reported studies that theirinvestigated ruthenium complexes also induced the activation of the caspase-mediated apoptosis pathway.[33,37]

3.3.4. Effect of the **RuL**complex on H2AX expressions

It is well known that apoptosis activation and subsequent DNA cleavage represent the main cytotoxic mode of action of metal-based antiproliferative drugs.[38]The current investigation showed that HepG2 cell exposure to **RuL**complex led to an increased proportion of apoptotic and necrotic cells. The complexresulted in the overexpression of H2AX expression level (**Figure 8**), which in turn confirmed the presence of DNA damage in HepG2. The present results corroborate previous studies that reported the induced apoptosis by ruthenium complexes.[39,40]

3.3.5. Effect of **RuL** treatment on VEGF in HepG2 cells

Vascular endothelial growth factor A (VEGF-A) is the main proangiogenic factor in the development, wound healing, and pathogenic conditions likecarcinogenesis.[41]It is highly expressed in cancer tissue and correlates with its more aggressive features. New blood vessel formation (angiogenesis) is a fundamental event in the process of tumor growth and metastatic dissemination.[42]In addition, the prosurvival activity of VEGF requires the phosphatidylinositol 3-kinase (PI 3-kinase)/Akt signal transduction pathway. Results of the current study manifested a significant reduction in gene expression and protein level of VEGF-A in the**RuL**-treated cells as compared to the untreated ones, **Figure 9A** and **B).** These findings supported the antiangiogenic activity of the **RuL** complex. *In vitro* studies of many ruthenium complexes have been previously identified as an inhibitor of angiogenesis.[43,44]

3.3.6. Effect of **RuL** complex on AKT and mTOR of HepG2 cells

The mammalian target of rapamycin (mTOR) is a highly conserved serine/threonine kinase that is frequently found in cancer and is regulated by several upstream regulators, including PI3/Akt.[45]The activation of the PI3K/Akt/mTOR signaling pathway has been linked to the promotion of VEGFA-induced proliferation, which in turn facilitates angiogenesis.[46] VEGF and PI3K/AKT/mTOR were two main pathways implicated in the carcinogenic process in HCC.[47]Besides VEGF-A, the mammalian target of rapamycin (mTOR) signaling pathway was also important in the regulation of cell proliferation, migration, survival, and angiogenesis, making it a promising target in HCC. mTOR plays an important role in regulating apoptosis and autophagy.[48] Results of this study revealed thatthe**RuL** inhibited angiogenesis by targeting the VEGFA-mediated Akt/mTOR signaling pathway. **RuL** also resulted in downregulation of the expression of Akt and mTOR as well as the protein of mTOR in HepG2 cells compared to untreated cells,**Figure 10**. The availability of VEGF, the critical modulator of tumor angiogenesis, was reduced as a result of such an influence on the expression level of these proteins. These findings showed that **RuL** disrupted a number of signaling pathways, resulting in changes in the activation and/or production of proteins involved in invasion and metastasis.

3.3.7. Effect of **RuL** complex on SND1 of HepG2 cells

The protein staphylococcal nuclease domain-containing protein 1 (SND1) is involved in several cellular biological processes, including gene transcription, pre-mRNA splicing, cell cycle, repair DNA damage, proliferation, programmed cell death, adipogenesis, and carcinogenesis.[49-52]Overexpression of SND1 promotes tumorigenesis in many types of cancer including HCC.[53-55]Furthermore, it was found that SND1 protein activated NF-kB, increased angiogenesis, and promoted human HCC cell migration and invasion[56], as well as playing a role in DNA damage[52]and the antiapoptotic pathway in HepG2.[57]SND1 contributes to the hallmarks of

cancer through several mechanisms, resulting in tumor aggressiveness and chemoresistance to various chemotherapeutic drugs. **RuL**-treated HepG2 cells reduced the expression of the mRNA gene and protein level of the SND1 compared to untreated HepG2 cells **Figure 11**. It was suggested that SND1 functions as an oncogene in HCC and contributes to cancer by a variety of mechanisms, implying that targeting SND1 could be a viable treatment option for HCC treatment.[58]

3.3.8. Effect of *RuL* complex on NF-kB in HepG2 cells

Nuclear Factor Kappa B (NF-kB) is a key signaling pathway that regulates hundreds of genes and is involved in a variety of events including cell proliferation, differentiation, development, and death.[48,59]Our study conveyed significant inhibition in the mRNA expression and protein level of NF-kB after treatment with **RuL** complex, as shown in**Figure 12**. NF-kB activation has been linked to many essential characteristics of carcinogenesis, including apoptosis inhibition, cancer initiation, tumor cell proliferation, and tumor development.[60]Inhibiting NF-kB sensitized cancer cells to treatment is considered one of the important targets for the development of chemotherapeutic agents.

3.4. Molecular docking of the ruthenium (*RuL*) complex

Molecular docking is an excellent approach to understand the interaction between the synthesized compounds and biological target. Analysis of the docking data is useful in predicting the conformational changes associated with the amino acid residues at the binding position to accommodate the docked hydrophobic inhibitors. The ruthenium complex (**RuL**) was subjected to molecular docking studies using the MOE version 2014.09 to understand the complex-targets interactions (binding poses) and to explore the potential binding mode and energy. The docked complex conformations were rated according to the binding affinity, hydrogen bonding and hydrophobic interactions between the complex and macromolecule. The macromolecule targets were: a B-DNA (PDB: 1BNA) andcaspase-3 protein (PDB: 3KJF). The docking studies determine the way by which the docked complex fundamentally fit in the macromolecule minor groove and comprise of hydrophobic, ionic, and hydrogen bonding interactions with the target bases. **Figure 13**illustrates the 2D and 3D molecular docking interaction representations of the ruthenium complex with the studied targets. The values of final score values (S) of the interactions of the ruthenium complex with the B-DNA and caspase-3 protein targets, which are related to the binding affinity, were-3.25 and -3.91 kcal/mol,respectively. Thus, the**RuL** complex showed good binding scores with high negative values that indicated high binding affinity between the receptors and the complex molecule. In addition, these values illustrate that the complex has high efficiency as a bioactive compound. In case of the 1BNA receptor, the binding interactions with the DNA came from either hydrophobic interactions between the amino acid residues (DG 22 and DA 5) or hydrogen bonding between the DA 6 region and both the coordinated water and nitrogen atoms of the coordinated Schiff base ligand, **Figure 13**. In case of caspase-3 protein (3KJF), the docked ruthenium molecule also showed good binding score (S = -3.91) as it formed hydrogen bonding with Asp 211 part and hydrophobic interactions with Lys 210 and Gln 217 moieties, **Figure 13**. Thus, it is obvious that these bioactive compounds were able to interacteffectively with the available binding sites of the studied targets.In addition, the molecular docking studiessupported the experimental findings.The increased value of total apoptosis of treated HepG2 cells with the **RuL** complex relative to the untreated ones could be due to the strong interaction of the complex with the DNA. Furthermore, the observed elevation in the activity of treated caspase 3 with ruthenium complex can be regarded due the possible binding interaction. The ability of the **RuL** complex to activate caspase 3 could be presumably demonstrated by the cell permeability concept and/or Tweedy's chelation theory.[61-63] The cell permeability concept declared that the polarity of the chelated metal ions is significantly reduced and improves the lipophilicity property and consequently the formed **RuL**-caspase 3 species would increase the caspase 3 activity.

IV. Conclusion

Anovel ruthenium-Schiff base complex was found to be a potentinhibitor of progression in HepG2 cells via induction of apoptosis and necrosis. *In vitro* studies indicated that the complex induced cell cycle arrest and apoptosis through damage of DNA and inhibition of the cell growth at the S phase pathway. Further, the complex increased the apoptotic related gene expression and possessed antiangiogenic activity by inhibiting VEGF, AKT/mTOR pathway, SND1 andNFkB gene expression. Molecular docking studies of the complex supported the increased total apoptosis of the treated HepG2 cells via strong interaction with DNA. The possible binding interaction of the Ru complex with caspase 3 could also be responsible for enhancing the activity of caspase 3 in treated HepG2 cells.

Supplementary Materials: The following are available online. **Figure 1S.** The IR spectrum of: **(A)** the Schiff base ligand**L**; **(B)RuL** complex; **Figure 2S.** The ^{1}HNMR spectrum of the Schiff base ligand; **Table 1S.** The primer sequences of tested genes.

Disclosure statement

The authors declare no conflict of interest.

Credit authorship contribution statement

The authors contributed to this work as follows: Safa W. Aziz: Experimental works, investigation and data curation; Amani F.H. Noureldeen: Supervision,formal analysis, writing original Draft, review, editingand visualization; Samia A. Shouman: Formal analysis, data curation and writing original draft; Magdy M. Mohamed: Supervision and data curation; Yasmin M. Attia: investigation and data curation;Ramadan M. Ramadan: Software and calculations, writing, review, editing final version and visualization;Mostafa M. Elhady: Supervision, data curationand writing original draft.

References

[1]. Singal, A. G.,Lampertico, P.&Nahon, P. Epidemiology and surveillance for hepatocellular carcinoma: New trends. *J. hepatol*. **72**, 250-261 (2020).

[2]. Petrick, J. L.*et al.*International trends in hepatocellular carcinoma incidence, 1978–2012. *Int. J. cancer***147**, 317-330 (2020).

[3]. Jafri, W.& Kamran, M. Hepatocellular carcinoma in Asia: a challenging situation. Euroasian*J. HepatoGastroenterology***9**, 27-33 (2019).

[4]. Ohata, J.& Ball, Z. T. Rhodium at the chemistry–biology interface. *Dalton Trans*. **47**, 14855-14860 (2018).

[5]. Lee, S. Y., Kim, C. Y.& Nam, T. G. Ruthenium complexes as anticancer agents: A brief history and perspectives. *Drug Des. Devel. Ther*. **14**, 5375-5392 (2020).

[6]. Ramadan, R.M.,Noureldeen, A.F.H., Abo-Aly, M.M.& El-Medani, S.M. Spectroscopic, DFT analysis, antimicrobial and cytotoxicity studies of three gold(III) complexes. *Inorg. Nano-Met. Chem*. **52**, 213-225 (2022).

[7]. Southam, H. M., Butler, J. A., Chapman, J. A.& Poole, R. K. The microbiology of ruthenium complexes. *Adv. Microb. Physiol*. **71**, 1-96 (2017).

[8]. Mahmud, M.,Niloy, M.S., Shakil, S.& Islam, A. Ruthenium Complexes: An Alternative to Platinum Drugs in Colorectal Cancer Treatment Kazi. *Pharmaceutics***13**, 1295 (2021).

[9]. Małecka,M.,Skoczyńska, A., Goodman, D.M.,Hartinger, C.G.&Budzisz, E. Biological properties of ruthenium(II)/(III) complexes with flavonoids as ligands. *Coord. Chem. Rev*. **436**, 213849 (2021).

[10]. Zhang, X., Liu, D.,Lv, F., Yu, B., Shen, Y.& Cong, H. Recent advances in ruthenium and platinum based supramolecular coordination complexes for antitumor therapy. *Colloids Surf. B: Biointerfaces***182**, 110373 (2019).

[11]. Mohamed, S.E., Ramadan, R.M.,Aboelhasan, A.E.& Abdel Aziz, A.A. Design, synthesis, biomedical investigation, DFT calculation and molecular docking of novel Ru(II)-mixed ligand complexes. *J. Biomol. Struct. Dyn*. 1-20 (2021).

[12]. Singh, A.& Barman, P. Recent advances in Schiff base ruthenium metal complexes: synthesis and applications. *Top. Curr. Chem*. **379**, 1-71 (2021).

[13]. Liu, J., Lai, H.,Xiong, Z., Chen, B.& Chen, T. Functionalization and cancer-targeting design of ruthenium complexes for precise cancer therapy. *Chem. Commun*. 55, 9904-9914 (2019).

[14]. Alessio, E.&Messori, L. NAMI-A and KP1019/1339, two iconic ruthenium anticancer drug candidates face-to-face: a case story in medicinal inorganic chemistry. *Molecules***24**, 1995 (2019).

[15]. Kapitza, S.*et al.*Heterocyclic complexes of ruthenium (III) induce apoptosis in colorectal carcinoma cells. *J. cancer Res. Clin. Oncol*. **131**, 101-110 (2005).

[16]. Lentz, F. In collaboration with Central European Society for Anticancer Drug Research-EWIV. Pharmacokinetics of a novel anticancer ruthenium complex (KP1019, FFC14A) in a phase I dose-escalation study. *Anti-cancer drugs***20**, 97-103 (2009).

[17]. Ramadan, R.M., Abu Al-Nasr, K.&Noureldeen, A.F.H. Synthesis, spectroscopic studies, antimicrobial activities and antitumor of a new monodentate V-shaped Schiff base and its transition metal complexes. *Spectrochim. Acta Part A***132**, 417-422 (2014).

[18]. Ramadan, R.M.,Elsheemy, W.M., Hassan N.S.& Abdel Aziz, A.A. Synthesis, spectroscopic characterization, thermal behavior and in vitro antimicrobial and anticancer activities of novel ruthenium tricarbonyl complexes containing monodentate V-shaped Schiff bases. *Appl. Organometal. Chem*. **32**, e4180 (2018).

[19]. Frisch, M. J.*et al*. Gaussian Inc., Wallingford, CT. 2009.

[20]. Skehan, P.*et al*. New colorimetric cytotoxicity assay for anticancer-drug screening. *JNCI***82**, 1107-1112 (1990).

[21]. Drew, H. R.*et al*. Structure of a B-DNA dodecamer: conformation and dynamics. *Proc. Natl. Acad. Sci*. **78**, 2179-2183 (1981).

[22]. Wang, Z.*et al*. Kinetic and structural characterization of caspase-3 and caspase-8 inhibition by a novel class of irreversible inhibitors. *Biochim. Biophys. Acta* **1804**, 1817-1831 (2010).

[23]. Taher, M. A.,Jarelnabbi, S. E., Al-Sehemi, A. G. M., El-Medani, S. M.& Ramadan, R. M. Synthesis and spectroscopic studies of some new metal carbonyl derivatives of 1-(2-pyridylazo)-2-naphthol. *J. Coord. Chem*. **62**, 1293-1301 (2009).

[24]. Ramadan, R. M.*et al*. Spectroscopic, DFT, non-linear optical properties and in vitro biological studies of Co(II), Ni(II) and Cu(II) complexes of hydrazide Schiff base derivatives. *Appl. Organometal. Chem*. e6246 (2021).

[25]. Yıldız, M.*etal*. Synthesis, biological activity, DNA binding and anion sensors, molecular structure and quantum chemical studies of a novel bidentate Schiff base derived from 3, 5-bis (triflouromethyl) aniline and salicylaldehyde. *J. Mol Struct*. **1094**, 148-160 (2015).

[26]. Hassen, S., Chebbi, H.,Zid, M. F.&Arfaoui, Y. Assembly and weak interactions in the crystal structure of 2-amino-4-(3-bromophenyl)-1, 3, 5-triazinobenzimidazolium chloride studied by X-ray diffraction, vibrational spectroscopy, Hirshfeld surface analysis and DFT calculations. *J. Mol. Struct*. **1179**, 678-684 (2019).

[27]. El-Medani, S. M.*et al*. Spectroscopic, crystal structural, theoretical and biological studies of phenylacetohydrazide Schiff base derivatives and their copper complexes. *J. Mol. Struct*. **1208**, 127860 (2020).

[28]. Raja, N., Ramesh, R.& Liu, Y. Paramagnetic ruthenium (III) complexes bearing O, O chelating ligands: Synthesis, spectra, molecular structure and electron transfer properties. *Polyhedron***31**, 196-201 (2012).

[29]. Aziz, A. A. A.,Elantabli, F. M.,Moustafa, H.& El-Medani, S. M. Spectroscopic, DNA binding ability, biological activity, DFT calculations and nonlinear optical properties (NLO) of novel Co (II), Cu (II), Zn (II), Cd (II) and Hg (II) complexes with ONS Schiff base. *J. Mol. Struct*. **1141**, 563-576 (2017).

[30]. Wan, D.*et al*. Synthesis and anticancer properties of ruthenium (II) complexes as potent apoptosis inducers through mitochondrial disruption. *Eur. J. Med. Chem*. **139**, 180-190 (2017).

[31]. Ryu, H.*et al*. The small molecule AU14022 promotes colorectal cancer cell death via p53-mediated G2/M-phase arrest and mitochondria-mediated apoptosis. *J. Cell. Physiol*. **233**, 4666–4676 (2018).

[32]. Zhang, H.W.*et al*. Flavonoids inhibit cell proliferation and induce apoptosis and autophagy through downregulation of PI3Kgamma mediated PI3K/AKT/mTOR/p70S6K/ULK signaling pathway in human breast cancer cells. *Sci. Rep*. **8**, 11255 (2018).

[33]. de Carvalho, N. C.*et al*. A novel ruthenium complex with xanthoxylin induces S-phase arrest and causes ERK1/2-mediated apoptosis in HepG2 cells through a p53-independent pathway. *Cell death dis.***9**, 1-24 (2018).

[34]. Jan, R.& Chaudhry, G.E. Understanding apoptosis and apoptotic pathways targeted cancer therapeutics. *Adv. Pharm. Bull*. **9**, 205-218 (2019).

[35]. Yadav, P., Yadav, R., Jain, S.& Vaidya, A. Caspase-3: A primary target for natural and synthetic compounds for cancer therapy. *Chem. Biol. Drug Des*. **98**, 144-165 (2021).

[36]. Qin, J.L.*et al*. Oxoaporphine metal complexes (CoII, NiII, ZnII) with high antitumor activity by inducing mitochondria-mediated apoptosis and S-phase arrest in HepG2, *Sci. Rep*. **7**, 46056 (2017).

[37]. Lu, Y., Shen, T., Yang, H.& Gu, W. Ruthenium Complexes Induce HepG2 Human Hepatocellular Carcinoma Cell Apoptosis and Inhibit Cell Migration and Invasion through Regulation of the Nrf2 Pathway. *Int. J. Mol. Sci*. **775**, 1-11 (2016).

[38]. Sahyon, H.A., El-Bindary, A.A., Shoair, A.F.&Abdellatif, A.A. Synthesis and characterization of ruthenium(III) complex containing 2-aminomethyl benzimidazole, and its anticancer activity of in vitro and in vivo models. *J. Mol. Liq*. **255**, 122-134 (2018).

[39]. Li, Y.*et al*. Polypyridyl Ruthenium(II) complex-induced mitochondrial membrane potential dissipation activates DNA damage-mediated apoptosis to inhibit liver cancer. *Eur. J. Med. Chem*. **164**, 282-291 (2019).

[40]. Neves, S. P. *et al*. Ruthenium complexes containing heterocyclic thioamidates trigger caspase-mediated apoptosis through MAPK signaling in human hepatocellular carcinoma cells. *Front. Oncol*. (2019). https://doi.org/10.3389/fonc.2019.00562.

[41]. Bourhis, M.,Palle, J.,Galy-Fauroux, I.& Terme, M. Direct and indirect modulation of T cells by VEGF-A counteracted by anti-angiogenic treatment. *Front. Immunol.***12**, 1-9 (2021).

[42]. Hicklin, D. J.& Ellis, L. M. Role of the vascular endothelial growth factor pathway in tumor growth and angiogenesis. *J. Clin. Oncol*. **23**, 1011-1027 (2005).

[43]. Kwong, W. L.*et al*. A Macrocyclic Ruthenium (III) Complex Inhibits Angiogenesis with Down-Regulation of Vascular Endothelial Growth Factor Receptor-2 and Suppresses Tumor Growth In Vivo. *Angew. Chem*. **128**, 13722-13726 (2016).

[44]. Brindell, M.,Gurgul, I.,Janczy-Cempa, E.,Gajda-Morszewski, P.&Mazuryk, O. Moving Ru polypyridyl complexes beyond cytotoxic activity towards metastasis inhibition. *J. Inorg. Biochem*. **226**, 111652 (2022).

[45]. Zhou, Z.*et al*. A VEGFR1 antagonistic peptide inhibits tumor growth and metastasis through VEGFR1-PI3K-AKT signaling pathway inhibition. *Am. J. Cancer Res.***5**, 3149-3161 (2015).

[46]. Husain, A., Khadka, A.,Ehrlicher, A., Saint-Geniez, M.& Krishnan, R. Substrate stiffening promotes VEGF-A functions via the PI3K/Akt/mTOR pathway. *Biochem. Biophys. Res. Commun*. **586**, 27-33 (2022).

[47]. Ferrín, G., Guerrero, M., Amado, V., Rodríguez-Perálvarez, M.& De la Mata, M. Activation of MTOR Signaling Pathway in Hepatocellular Carcinoma. *Int. J. Mol. Sci*. **21**, 1266 (2020).

[48]. Zinatizadeh, M. R.*et al*. The Nuclear Factor Kappa B (NF-kB) signaling in cancer development and immune diseases. *Genes dis*. **8**, 287-297 (2021).

[49]. Duan, Z.*et al*. Tudor-SN, a novel coactivator of peroxisome proliferator-activated receptor gamma protein, is essential for adipogenesis. *J Biol Chem*. **289**, 8364-8374 (2014).

[50]. Yu, L.*et al*. SND1 acts downstream of TGFbeta1 and upstream of Smurf1 to promote breast cancer metastasis. *Cancer Res*. **75**, 1275-1286 (2015).

[51]. Su, C.*et al*. Tudor staphylococcal nuclease(Tudor-SN), a novel regulator facilitating G1/S phase transition ,acting as a co-activator of E2F-1 in cell cycle regulation. *J Biol Chem*. **290**, 7208-7220 (2015).

[52]. Fu, X.*et al*. Oncoprotein Tudor-SN is a key determinant providing survival advantage under DNA damaging stress. *Cell Death Differ*. **25**, 1625-1637 (2018).

[53]. Santhekadur, P. K.*et al*. Staphylococcal nuclease domain containing-1 (SND1) promotes migration and invasion via angiotensin II type 1 receptor (AT1R) and TGFβ signaling. *FEBS open bio*. **4**, 353-361 (2014).

[54]. Gutierrez-Beltran, E., Denisenko, T. V.,Zhivotovsky, B.&Bozhkov, P. V. Tudor staphylococcal nuclease: biochemistry and functions. *Cell Death Differ*. **23**, 1739-1748 (2016).

[55]. Zhou, M.*et al*. SND1 promotes the proliferation of osteosarcoma cells by upregulating COX 2/PGE2 expression via activation of NF κB. *Oncology reports*. **41**, 579-589 (2019).

[56]. Jariwala, N.*et al*. Oncogenic role of SND1 in development and progression of hepatocellular carcinoma. *Cancer Res*. **77**, 3306-3316 (2017).

[57]. Cui, X.*et al*. SND1 acts as an anti-apoptotic factor via regulating the expression of lncRNA UCA1 in hepatocellular carcinoma. *RNA Biol*. **15**, 1364-1375 (2018).

[58]. Chidambaranathan-Reghupaty, S., Mendoza, R., Fisher, P. B.& Sarkar, D. The multifaceted oncogene SND1 in cancer: focus on hepatocellular carcinoma. *Hepatoma Res*. **4**, 1-14 (2018).

[59]. Song, W.,Mazzieri, R., Yang, T.&Gobe, G.C. Translational significance for tumor metastasis of tumor-associated macrophages and epithelial-mesenchymal transition. *Front. Immunol*. **8**, 1106 (2017).

[60]. Xia, Y., Shen, S.& Verma, I.M. NF-kappaB, an active player in human cancers. *Cancer Immunol. Res*. **2**, 823-830 (2014).

[61]. Tweedy, B. G. *Phytopathology***55**, 910 (1964).

[62]. Deamer, D. W.,Kleinzeller, A.&Fambrough, D.M. *Membrane Permeability: 100 Years since Ernest Overton*, Current Topics in Membranes, 48 (Academic Press, San Diego, CA, 1999)

[63]. Smith,N.A.*et al*.Combatting AMR: photoactivatable ruthenium(II)-isoniazid complex exhibits rapid selective antimycobacterial activity.*Chem. Sci*. **8**, 395-404 (2017).

Captions to Figures:
Figure 1. Synthesis of the ligand and ruthenium complex.
Figure2. (A) The geometrically optimized structure and the charge distribution on atoms of the ligand**L** (atoms are colored according to their charges). **(B)** The geometrically optimized structure of the ruthenium complex**RuL**.
Figure 3. The HOMO and LUMO charge densities and surface contour maps of the ligand and its ruthenium complex.
Figure 4. (A) The effect of **RuL** complex on the proliferation of thetested cell lines;**(B)**The effect of cisplatin toward the proliferation of HepG2.Data is presented as the means of triplicate measurements from three independent experiments.
Figure 5. Cell cycle distribution upon treatment with **RuL** on HepG2 cells:**(A)**The untreated control;**(B)**The treatment of cells by **RuL**; **(C)** The effect of **RuL**on the cell cycle distribution of HepG2 cells;**(D)** Cell population against cell cycle phases. Data are expressed as mean ± SD performed in triplicate. Statistical differences were analyzed with T-test. * Significant at $P<0.05$.
Figure 6. Effect of **RuL** on the cell death of HepG2 cells by flow cytometry using Annexin V-FITC/PI staining:**(A)**Untreated HepG2 cells (control); **(B) RuL**-treated HepG2cells;**(C)** The effect of **RuL**on the cell apoptosis in HepG2 cells. **(D)** Cell population against apoptosis phases.Data are given as mean ± SD performed in triplicate. Statistical differences were analyzed with *T*-test. * Significant at $P <0.05$.
Figure7. Effect of the **RuL** complex on the caspase-3 and -7 activities in HepG2 cells:**(A)** Expression of caspase-3; **(B)** Caspase-3 activity; **(C)** Expression of caspase-7.Data are expressed as mean ± SD of 2 independent experiments performed in triplicate. Statistical differences were analyzed with *T*-test. * Significant at $P <0.05$.
Figure 8. Effect of the **RuL**complex on H2AX expressionsin HepG2 cells as determined by RT-PCR. Data are given as mean ± SD of 2 independent experiments performed in triplicate. Statistical differences were analyzed with *T*-test. * Significant at $P<0.05$.
Figure 9. Effect of **RuL** treatment on VEGF in HepG2 cells:**(A)** RT-PCR gene expression;**(B)** protein level. Results are expressed as mean ± SD of 2 independent experiments performed in triplicate. Statistical differences were analyzed with *T*-test. * Significant at $P <0.05$.
Figure 10. Effect of **RuL** complex on AKT and mTOR of HepG2 cells:**(A)** Relative mRNA expression and protein level of mTOR; **(B)** Effect of different concentration of mTOR; **(C)** Relative mRNA expression of AKT. Data are plotted as mean ± SD of 2 independent experiments performed in triplicate. Statistical differences were analyzed with *T*-test. *Significant at $P <0.05$.
Figure 11. Effect of **RuL** complex on SND1 of HepG2 cells:**(A)**Gene expression;**(B)** protein level. Results are expressed as mean ± SD of 2 independent experiments performed in triplicate. Statistical differences were analyzed with *T*-test. *Significant at $P <0.05$.
Figure 12. Effect of **RuL** complex on NF-kB in HepG2 cells:**(A)**Gene expression;**(B)** protein levels. Data are expressed as mean ± SD of 2 independent experiments performed in triplicate. Statistical differences were analyzed with *T*-test. *Significant at $P <0.05$.
Figure 13. Molecular docking interactions (2D and 3D) of the**RuL** complex with DNA (1BNA) and caspase 3 (3KJF).

Table 1. Important bond lengths and bond angles for the ligand and its ruthenium complex.

	L				RuL			
Bond length (Å)	C(12)-N(15)	1.40	C(8)-N(15)	1.28	C(15)-N(11)	1.43	C(10)-N(11)	1.29
	C(12)-N(11)	1.36	C(12)-N(13)	1.35	Ru(30)-O(34)	2.19	Ru(30)-Cl(31)	2.41
	C(4)-N(18)	1.47	C(1)-Cl(7)	1.82	C(3)-Cl(38)	1.81	C(6)-N(12)	1.48
					Ru(30)-N(20)	2.11	Ru(30)-N(11)	2.10
Bond angle (°)	C(8)-N(15)-C(12)	131.0	N(11)-C(12)-N(13)	125.8	C(10)-N(11)-C(15)	123.6	N(20)-Ru(30)-O(34)	78.0
	C(2)-C(1)-Cl(7)	118.9	C(5)-C(8)-N(15)	127.6	N(11)-Ru(30)-N(20)	64.2	Cl(32)-Ru(30)-O(34)	171.6
	C(4)-N(18)-O(20)	118.0	C(6)-C(5)-C(8)	118.5	Cl(32)-Ru(30)-Cl(33)	105.6	N(11)-C(15)-N(20)	103.5
	N(11)-C(12)-N(15)	123.2						

Table 2. The quantum global reactivity descriptors for **L** and **RuL** complex.

Parameter	L	RuL
DM (Debye)	5.22	13.44
HOMO (eV)	-6.61	-6.47
LUMO (eV)	-3.33	-3.82
ΔE (eV)	3.28	2.64
X (eV)	4.97	5.15
V (eV)	-4.97	-5.15
A (eV)	3.33	3.82
I (eV)	6.61	6.47
η (eV)	1.64	1.32
S (eV)	0.82	0.66
ω (eV)	7.53	10.02